Proven safe and effective in laboratory trials, the procedure will undergo human clinical trials beginning in 2010.

TrichoScience is also researching a number of other cell-based procedures.

Dr. Rolf Hoffmann, MD
President

Naja, kennt man ja alles schon so oder so ähnlich.

Intercytex wollte uns das ähnlich und auch als genau so einfach verkaufen, was draus geworden ist, wissen wir ja ...

Bei Tricho tauchen letztlich auch wieder die selben fragen wie Wuchsrichtung usw.

Ich lass mich ja gerne seitens der Firma vom Gegenteil überzeugen. Allerdings glaube ich nicht das da in den nächsten 10 Jahren was marktreifes bei rauskommt.

VANCOUVER, BRITISH COLUMBIA -- (Marketwire) -- 09/20/10 -- Berkley Resources Inc. (CNSX: BKS)(PINK SHEETS: BRKDF)(FRANKFURT: W8O) reports it has purchased 200,000 common shares of Vancouver-based TrichoScience Innovations Inc. at a price of CDN$1.00 per share. TrichoScience, a privately-held Life Sciences company, has developed and patented a new hair cell replication technology called Replicel™ that has the potential to become an effective, non-surgical treatment for pattern baldness and other forms of hair loss in both men and women. Berkley's share purchase represents 2.13% of TrichoScience's issued and outstanding share capital.

The Replicel™ procedure is based on autologous cell implantation technology that replicates a patient's hair cells from their own healthy hair follicles. When reintroduced into areas of hair loss, the replicated cells initiate natural hair regeneration. Replicel™ will undergo Stage 1 Human Clinical Trials beginning in late 2010. For more information about TrichoScience and Replicel™ visit www.trichoscience.com.

ABOUT BERKLEY RESOURCES INC.

Berkley is a growth-oriented and diversified venture company pursuing opportunities in both Canada and the United States. The company's shares trade on the Canadian National Stock Exchange (CNSX) under the symbol BKS and in the U.S. under the symbol BRKDF.

For more information visit: www.berkleyresources.com.